研究简报

抗癌药物达卡巴嗪的合成工艺优化

  • 肖胜伟 ,
  • 刘志军 ,
  • 柳杨 ,
  • 陈河如
展开
  • a 暨南大学药学院中药及天然药物研究所 广州 510632;
    b 广东省中药药效物质基础及创新药物研究重点实验室 广州 510632

收稿日期: 2014-10-18

  修回日期: 2014-12-19

  网络出版日期: 2015-01-07

基金资助

国家自然科学基金(No.81172982)资助项目.

Optimization of the Synthetic Process of Antineoplastic Drug Dacarbazine

  • Xiao Shengwei ,
  • Liu Zhijun ,
  • Liu Yang ,
  • Chen Heru
Expand
  • a Institute of Traditional Chinese Medicine and Natural Products, College of Pharmacy, Jinan University, Guangzhou 510632;
    b Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, Jinan University, Guangzhou 510632

Received date: 2014-10-18

  Revised date: 2014-12-19

  Online published: 2015-01-07

Supported by

Project supported by the National Natural Science Foundation of China (No.81172982).

摘要

以廉价易得的甘氨酸为原料, 经酯化、甲酰化、脱水、酰氨化得到异氰基乙酰胺, 四步总收率42.9%. 异氰基乙酰胺与氨基腈在碱性条件下环合得到重要中间体5-氨基-4-咪唑甲酰胺, 收率68.2%. 随后经重氮化, 与二甲胺偶联, 得最终产物达卡巴嗪, 总收率22.3%. 所有中间体以及目标产物的结构均由1H NMR, 13C NMR和ESI-MS确证. 合成路线具有原料廉价、反应条件温和、总收率较高等特点, 是一条经济实用的合成工艺路线.

本文引用格式

肖胜伟 , 刘志军 , 柳杨 , 陈河如 . 抗癌药物达卡巴嗪的合成工艺优化[J]. 有机化学, 2015 , 35(5) : 1161 -1165 . DOI: 10.6023/cjoc201410026

Abstract

Dacarbazine has been prepared started from glycine, which was carried on firstly through a four-step process including esterification, formylation, dehydration, amidation to give 2-isocyanoacetamide with a total yield of 42.9%. 2-Isocyanoacetamide was then cyclized with cyanamide under basic condition to afford the important intermediate 5-amino-1H-imidazole-4-carboxamide with yield of 68.2%. This intermediate undergoing diazotization and following coupling reaction with dimethylamine led to the target compound. The overall yield was 22.3%. All the intermediates and the target products dacarbazine were confirmed by 1H NMR, 13C NMR and ESI-MS. The current process is economic efficient charac-terized by applied cheap materials, mild conditions, and good overall yield.

参考文献

[1] Wexler, P. In Encyclopedia of Toxicology, 3rd ed., Ed.: Andrea, M., Manchester, 2014, pp. 1132~1134.
[2] Zheng, M.; Sun, G. J. J. Pract. Oncol. 1998, 13(6), 328 (in Chinese). (郑敏, 孙国君, 实用肿瘤学杂志, 1998, 13(6), 328.)
[3] Pretto, F.; Elia, G.; Castioni, N.; Neri, D. Cancer Immunol. Immunother. 2014, 63(9), 901.
[4] Alexandrina, C.; Cornea, F.; Ionescu, C. D. RO 80163, 1983 [Chem. Abstr. 1984, 101, 151849].
[5] Jain, M. L.; Tsao, Y. P.; Ho, N. L.; Cheng, J. W. J. Org. Chem. 2001, 66, 6472.
[6] Mitsuru, T.; Masami, H.; Yoshikazu, I. JP 544941, 2004 [Chem. Abstr. 2004, 354906].
[7] Chaudhary, S.; Singh, K. R. Asian J. Pharm. Clin. Res. 2012, 5(4), 196.
[8] Panella, L.; Aleixandre, A. M.; Kruidhof, G. J.; Robertus, J. J. Org. Chem. 2006, 71, 2026.
[9] Tomasz, G.; Robert, H.; Scott, H. US 13983747, 2013 [Chem. Abstr. 2012, 157, 383004].
[10] Elders, N.; Ruijter, E.; Frans, J. J. Chem. Eur. J. 2009, 15, 6096.
[11] Elders, N.; Ruijter, E.; Frans, J. J. Chem. Eur. J. 2008, 14, 4961.
[12] Murakami, T.; Otsuka, M.; Ohno, M. Tetrahedron Lett. 1982, 23(45), 4729.
[13] Saladino, R.; Crestini, C.; Ciambecchini, U.; Ciciriello, F.; Cos-tanzo, G.; Di Mauro, E. ChemBioChem 2004, 5, 1558.

文章导航

/